Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
Mallinckrodt plc (MNK) delivers specialty pharmaceutical solutions and medical imaging innovations across autoimmune, rare disease, and diagnostic markets. This news hub provides investors and healthcare professionals with essential updates on the company’s strategic developments and regulatory milestones.
Access timely reports on earnings announcements, product approvals, research advancements, and partnership agreements. Our curated collection features official press releases alongside verified third-party coverage of MNK’s activities in specialty generics, contrast media production, and therapeutic pipeline progress.
Key content categories include financial performance updates, manufacturing capacity expansions, intellectual property developments, and compliance-related communications. Track MNK’s progress in neurology, rheumatology, and nephrology treatment innovations through objective reporting of material events.
Bookmark this page for streamlined monitoring of Mallinckrodt’s operational updates and market positioning. Check back regularly for authoritative coverage of this specialty pharma leader’s initiatives in addressing complex healthcare challenges through advanced biopharmaceutical solutions.
Mallinckrodt and Endo have announced a strategic merger to create a global pharmaceuticals leader through a stock and cash transaction. The deal, expected to close in H2 2025, will see Endo shareholders receive $80 million in cash and own 49.9% of the combined entity, while Mallinckrodt shareholders will own 50.1%.
The combined company, to be listed on the NYSE, projects $3.6 billion in 2025 revenue and $1.2 billion in Adjusted EBITDA. The merger aims to generate at least $150 million in annual operating synergies by Year 3 and approximately $75 million in Year 1.
Key aspects include a net leverage of 2.3x at close, 17 manufacturing facilities, 30 distribution centers, and approximately 5,700 employees. The companies plan to combine and later separate their generics and sterile injectables businesses. Siggi Olafsson will serve as CEO of the combined entity, with Paul Efron as Board Chair.
Mallinckrodt plc (MNK), a global specialty pharmaceutical company, has rescheduled its fourth quarter and fiscal year 2024 financial results release to Thursday, March 13, 2025, before market open. The earnings conference call for investors will begin at 8:00 a.m. ET.
The company operates through two main segments: Specialty Brands, focusing on autoimmune and rare diseases in areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology, along with neonatal respiratory critical care therapies and gastrointestinal products; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
Mallinckrodt has scheduled the release of its fourth quarter and fiscal year 2024 financial results for Tuesday, March 11, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:00 a.m. ET on the same day. Participants can access the call through registration links provided, with options including an audio-only webcast and replay availability through the company's Investor Relations webpage.
Mallinckrodt has completed the sale of its Therakos business to CVC Capital Partners Fund IX for $925 million. The transaction will enable the company to reduce its net debt by more than 60% using the net proceeds. The divestiture aligns with Mallinckrodt's strategic priorities to optimize its capital structure and focus on core strengths. Lazard acted as financial advisor, while Wachtell, Lipton, Rosen & Katz served as primary legal counsel for the transaction.
Mallinckrodt presented data on TERLIVAZ (terlipressin) for hepatorenal syndrome (HRS) at the 2024 AASLD Annual Meeting. The research analyzed pooled data from three Phase 3 studies, evaluating HRS reversal after 12 doses. Results showed 33.6% reversal rate in the TERLIVAZ group versus 16.8% in placebo. Notably, 94.9% of patients achieving HRS reversal required more than 12 doses. TERLIVAZ is the first FDA-approved treatment for improving kidney function in adults with HRS, a condition affecting approximately 42,000 Americans annually.
Mallinckrodt plc has announced its participation in the upcoming Jefferies London Healthcare Conference. Siggi Olafsson, President and Chief Executive Officer, will deliver a presentation on Tuesday, November 19, 2024, at 9:30 a.m. GMT/4:30 a.m. ET. For those unable to attend in person, a webcast will be available online, with a replay option provided after the event.
Mallinckrodt reported Q3 2024 net sales of $505.5 million, up 1.7% year-over-year. The company raised its full-year Adjusted EBITDA guidance to $590-620 million while reaffirming net sales guidance of $1.9-2.0 billion. Acthar Gel achieved its third consecutive quarter of growth, with sales up 3.5% to $126.4 million, leading to expectations of approximately 10% growth for full-year 2024. The Specialty Generics segment reported 4.1% growth to $219.5 million. The company expects to reduce net debt by more than 60% in Q4 following the sale of Therakos business for $925 million to CVC Capital Partners.
Mallinckrodt announced the presentation of four posters on TERLIVAZ® (terlipressin) at The Liver Meeting 2024. The research focuses on patients with hepatorenal syndrome (HRS) with rapid kidney function reduction, affecting approximately 42,000 Americans annually.
The presentations include pooled data from Phase 3 studies examining: the impact of waiting until Day 4 for assessing HRS reversal, the effect of obesity on HRS reversal, and outcomes in patients treated with standard versus high doses. An additional analysis from the CONFIRM study explores TERLIVAZ's impact on HRS reversal, liver transplant rates, and MELD scores.
TERLIVAZ is the first FDA-approved treatment to improve kidney function in adults with HRS with rapid reduction in kidney function, a rare and life-threatening condition requiring hospitalization.
Mallinckrodt presented real-world data on TERLIVAZ (terlipressin) for hepatorenal syndrome-acute kidney injury (HRS-AKI) at the ACG Annual Meeting. The analysis, based on 125 hospitalized patients, revealed that 74.4% had underlying alcoholic liver disease, with 97.6% being emergent/urgent admissions. The in-hospital mortality rate was 17.6%, and TERLIVAZ was used as first-line treatment in 20.8% of cases. Among patients with available serum creatinine data (n=21), 47.6% achieved HRS reversal. The study highlights treatment challenges in HRS-AKI patients at high risk of death.
Mallinckrodt presented data on TERLIVAZ (terlipressin) for hepatorenal syndrome (HRS) at Kidney Week 2024. The presentation featured a pooled analysis from Phase 3 trials (CONFIRM and REVERSE) examining treatment outcomes in HRS patients. Key findings showed that in patients listed for liver transplant at baseline, TERLIVAZ treatment resulted in 43% HRS-AKI reversal rate compared to 20% in the placebo group. The treatment also reduced the need for renal replacement therapy while maintaining similar liver transplant rates between groups. TERLIVAZ is the first FDA-approved product for improving kidney function in adults with HRS, a condition affecting approximately 42,000 Americans annually.
